• Molecular NameCefepime
  • SynonymCefepima [spanish]; Cefepimum [latin]
  • Weight480.57
  • Drugbank_IDDB01413
  • ACS_NO88040-23-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-3.41
  • pka1.39, and 3.26
  • LogD (pH=7, predicted)-5.91
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.62
  • LogSw (predicted, AB/LogsW2.0)303.06
  • Sw (mg/ml) (predicted, ACD/Labs)143.71
  • No.of HBond Donors4
  • No.of HBond Acceptors11
  • No.of Rotatable Bonds7
  • TPSA200.75
  • StatusFDA approved
  • AdministrationIntravenous, intramuscular
  • PharmacologyA fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding17.5
  • Volume of distribution (VD)0.26 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic 15%
  • Half life2.1 h
  • ExcretionRenal 70–99%
  • Urinary Excretion80
  • Clerance1.8 ml/min/kg
  • ToxicityMost common adverse reactions are headache, nausea, vomiting, diarrhea, colitis, including pseudomembranous colitis, oral moniliasis, rash, pruritus, urticaria.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A